INZY News and Press, Inozyme Pharma Inc. From 09/08/21

Gainers: Kadmon (NASDAQ:KDMN) +73%. ICU Medical (NASDAQ:ICUI) +32%. Candel Therapeutics (NASDAQ:CADL) +23%. Globalstar (NYSE:GSAT) +22%. Spectrum Brands (NYSE:SPB) +20%. Vinco Ventures (NASDAQ:BBIG) +19%. WISeKey (NASDAQ:WKEY) +14%. SilverBow (NYSE:SBOW) +16%. Aterian (NASDAQ:ATER) +16%. Gain...

Gainers: Kadmon KDMN +73%, ICU Medical ICUI +32%, Candel Therapeutics CADL +17%, Gain Therapeutics GANX +9%, Concord Medical Services (NYSE:CCM) +9%. Losers: INmune Bio (NASDAQ:INMB) -22%, Inozyme Pharma (NASDAQ:INZY) -19%, Alector A...

- Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency – – Clinical Trial Application in Europe accepted for Phase 1/2 trial of INZ-701 in ABCC6 Deficiency – – Investigational...

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief...

Gainers: Oragenics OGEN +58%, EyeGate Pharmaceuticals (EYEG) +54%, Dyadic DYAI +29%, ObsEva OBSV +27%, U.S. Physical Therapy (USPH) +15%.Losers: Infinity Pharmaceuticals INFI -30%, NanoVibronix (NAOV) -22%, ATI Physical Therapy (ATIP...

BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designatio...

Inozyme Pharma (INZY) announces that Gayle Gironda has been appointed as senior vice president of human resources.Gironda is a human resources leader with more than 20 years of experience in organizational design, talent recruitment, performance culture, planning and leade...

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that Gayle Gironda has been appointed as senior vice president of human res...

- Clinical trial initiation expected in mid-2021 – - Preliminary safety and biomarker data expected by the end of 2021 - BOSTON, June 09, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeu...

– Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe; on track to initiate Phase 1/2 clinical trial in mid-2021 – – Published peer-reviewed preclinical data supporting INZ-701 as a potential treatment for ENPP1 Deficiency in Journa...